The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided:
[wherein, R
1
represents a group —X-Q
1
, X-Q
1
-Y-Q
2
or X-Q
1
-Y-Q
2
-Z-Q
3
, X represents a single bond, —CH
2
— or the like, Q
1
represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH
2
—, or the like, Q
2
represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR
11
R
12
— or the like, R
11
and R
12
each independently represents a hydrogen atom, a halogen atom or the like, Q
3
represents a phenyl group which may have substituent(s), a C
3
-C
7
cycloalkyl group which may have substituent(s), a C
3
-C
7
cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R
2
represents a C
1
-C
3
alkyl group or the like, and R
3
represents a hydrogen atom or a methyl group].